Cargando…

Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice

Nonalcoholic fatty liver disease (NAFLD) is an increasingly prevalent chronic liver disease for which no approved therapies are available. Despite intensive research, the cellular mechanisms that mediate NAFLD pathogenesis and progression are poorly understood. Although obesity, diabetes, insulin re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Mei, Learned, R. Marc, Rossi, Stephen J., DePaoli, Alex M., Tian, Hui, Ling, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721409/ https://www.ncbi.nlm.nih.gov/pubmed/29404440 http://dx.doi.org/10.1002/hep4.1108

Ejemplares similares

Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis
por: Branković, Marija, et al.
Publicado: (2022)

Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis
por: Zhou, Mei, et al.
Publicado: (2019)

FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis
por: Liu, Cong, et al.
Publicado: (2023)

New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis
por: Mendez-Sanchez, Nahum, et al.
Publicado: (2018)

Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases
por: Sanyal, Arun J., et al.
Publicado: (2021)

Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2‐deficient mice
por: Zhou, Mei, et al.
Publicado: (2016)

Circulating Citrate Is Associated with Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
por: Amjad, Waseem, et al.
Publicado: (2023)

NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis
por: Harrison, Stephen A., et al.
Publicado: (2019)

Targeting bile acids and lipotoxicity for NASH treatment
por: Chiang, John Y. L.
Publicado: (2017)

Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
por: Armstrong, Matthew J., et al.
Publicado: (2016)

STUDIES ON THE TOXICITY OF BILE : II. THE TOXIC EFFECTS OF BILE UPON THE CENTRAL NERVOUS SYSTEM AND THE ELIMINATION OF STRYCHNINE THROUGH THE BILE IN NEPHRECTOMIZED ANIMALS.
por: Meltzer, S. J., et al.
Publicado: (1906)

The Commensal Microbe V eillonella as a Marker for Response to an FGF19 Analog in NASH
por: Loomba, Rohit, et al.
Publicado: (2020)

Regulation of Hepatocyte Nuclear Factor 4α Attenuated Lipotoxicity but Increased Bile Acid Toxicity in Non-Alcoholic Fatty Liver Disease
por: Roh, Yoon Jin, et al.
Publicado: (2022)

Analysis of probable lipotoxic damage and myocardial fibrosis in epicardial obesity
por: Chumakova, Galina, et al.
Publicado: (2021)

Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis
por: Puengel, Tobias, et al.
Publicado: (2022)

Myristic acid potentiates palmitic acid-induced lipotoxicity and steatohepatitis associated with lipodystrophy by sustaning de novo ceramide synthesis
por: Martínez, Laura, et al.
Publicado: (2015)

Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis
por: Tsuji, Yuki, et al.
Publicado: (2020)

Engineered autocrine signaling eliminates muscle cell FGF2 requirements for cultured meat production
por: Stout, Andrew J., et al.
Publicado: (2023)

Bile acids contribute to the development of non-alcoholic steatohepatitis in mice
por: Gillard, Justine, et al.
Publicado: (2021)

Role of Glucuronidation for Hepatic Detoxification and Urinary Elimination of Toxic Bile Acids during Biliary Obstruction
por: Perreault, Martin, et al.
Publicado: (2013)

The selective peroxisome proliferator–activated receptor‐delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice
por: Haczeyni, Fahrettin, et al.
Publicado: (2017)

Role of aramchol in steatohepatitis and fibrosis in mice
por: Iruarrizaga‐Lejarreta, Marta, et al.
Publicado: (2017)

Intragastric Balloon Improves Steatohepatitis and Fibrosis
por: Lin, Elissa, et al.
Publicado: (2021)

Overexpression of Hepcidin Alleviates Steatohepatitis and Fibrosis in a Diet-induced Nonalcoholic Steatohepatitis
por: Chen, Hui, et al.
Publicado: (2022)

Carvedilol impairs bile acid homeostasis in mice: implication for nonalcoholic steatohepatitis
por: Lastuvkova, Hana, et al.
Publicado: (2023)

Sexual dimorphism in inorganic mercury toxicokinetics and the attendant lipotoxic and non-lipotoxic dyslipidemia in the rat
por: Wusu, A.D., et al.
Publicado: (2021)

FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases
por: Tillman, Erik J., et al.
Publicado: (2020)

Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice
por: Yu, Youxi, et al.
Publicado: (2021)

Correction: Role of Glucuronidation for Hepatic Detoxification and Urinary Elimination of Toxic Bile Acids during Biliary Obstruction
por: Perreault, Martin, et al.
Publicado: (2014)

Invited Perspective: Eliminating Toxics to Prevent Disease: Asbestos Leads the Way
por: Kriebel, David, et al.
Publicado: (2022)

Common sense purchasing: hard knock lessons learned from a purchasing pro
por: DePaoli, Tom
Publicado: (2004)

Suppression of Hepatic Bile Acid Synthesis by a non-tumorigenic FGF19 analogue Protects Mice from Fibrosis and Hepatocarcinogenesis
por: Gadaleta, Raffaella Maria, et al.
Publicado: (2018)

Glutamine Modulates Macrophage Lipotoxicity
por: He, Li, et al.
Publicado: (2016)

The Role of Lipotoxicity in Smoke Cardiomyopathy
por: Santos, Priscila P., et al.
Publicado: (2014)

Dual role of neutrophils in modulating liver injury and fibrosis during development and resolution of diet-induced murine steatohepatitis
por: Kim, Andrea D., et al.
Publicado: (2021)

Atorvastatin Modulates Bile Acid Homeostasis in Mice with Diet-Induced Nonalcoholic Steatohepatitis
por: Lastuvkova, Hana, et al.
Publicado: (2021)

Kaempferol attenuates nonalcoholic steatohepatitis by regulating serum and liver bile acid metabolism
por: Lu, Yifei, et al.
Publicado: (2022)

Disulfiram ameliorates nonalcoholic steatohepatitis by modulating the gut microbiota and bile acid metabolism
por: Lei, Yuanyuan, et al.
Publicado: (2022)

The Role of FGF19 and MALRD1 in Enterohepatic Bile Acid Signaling
por: Wang, Linda X., et al.
Publicado: (2022)

Icosabutate Exerts Beneficial Effects Upon Insulin Sensitivity, Hepatic Inflammation, Lipotoxicity, and Fibrosis in Mice
por: van den Hoek, Anita M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mdvccuufn59m4ti9nli1knv4os